Phase 2 Brain Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a specific type of aggressive brain tumour (WHO grade 4 glioma) confirmed by laboratory testing, and for whom surgery to remove the tumour is already planned.
• People who have never previously taken sitagliptin (also known as a "gliptin") as a medication.
• People who, in the opinion of their doctor, are able to tolerate a low dose of a steroid medication called dexamethasone (or a similar steroid) before surgery.
• People aged 18 years or older.
• People who have a reasonable level of general physical functioning, as assessed by their doctor using a standard scale (confirm with trial site).
• People whose blood counts, liver function, and kidney function are within acceptable ranges based on blood tests taken within the three weeks before joining the study.
• People taking full-dose blood-thinning medications (such as warfarin or heparin), provided they have no active bleeding or high bleeding risk, and their blood-thinning levels are stable and within a safe range.
• Women who could become pregnant must have a negative pregnancy test within three weeks of joining, and both women who could become pregnant and men who could father children must agree to use reliable contraception during the study and for 30 days after the last dose of the study drug.
• People who are able to swallow whole tablets.
• People who have waited the required amount of time since any previous treatments (e.g., at least 4 weeks since surgery, 6 weeks since certain chemotherapy types, and specific intervals for other treatments — confirm with trial site).
• People living with HIV may be eligible, provided their virus levels are undetectable within 6 months before joining, they are on a stable HIV treatment regimen, and they do not need preventative antibiotics or antifungal medicines.
• People with a past hepatitis C infection may be eligible if they have been successfully treated and cured, or if they are currently on treatment with undetectable virus levels.
• People with a chronic hepatitis B infection may be eligible if their virus levels are undetectable on appropriate treatment; people who are immune to hepatitis B (e.g., through vaccination) are also eligible.
• People who their doctor considers suitable for chemotherapy after surgery.
• People who are able to understand the study and are willing to sign a consent form.

Who may not be able to join:

• People who still have significant side effects from previous treatments that have not resolved (except hair loss or nerve-related symptoms).
• People who are currently participating in another clinical trial involving an experimental treatment.
• People who have had an allergic reaction to sitagliptin or medications with a similar chemical make-up.
• People with poorly controlled diabetes.
• People who currently require insulin or a specific type of diabetes medication called a sulfonylurea.
• People who have a documented history of dangerously low blood sugar requiring medical treatment, or who their doctor considers unsuitable for sitagliptin.
• People with serious uncontrolled illness, such as an active infection, unstable heart conditions, or mental health or personal circumstances that would make it difficult to follow the study requirements.
• People with another cancer (past or current) whose disease or treatment could interfere with the safety or results of this trial (confirm with trial site, as some prior cancers may still be acceptable).
• People with a significant long-term bowel condition where diarrhoea is a major symptom (such as Crohn's disease), or who have moderate or severe diarrhoea at the time of screening.
• People who are pregnant or breastfeeding.
• People who are unable or unwilling to swallow tablets.
• People whose overall health, blood test results, or personal circumstances their doctor considers would make participation in this study inappropriate.

Important: Always verify eligibility with the trial site directly before applying.